SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

39.02

22-November-24 16:44:58

15 minutes delayed

Stocks

+2.72

+7.49%

Today's range

36.24 - 39.61

ISIN

N/A

Source

NASDAQ

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

30 Aug 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

04 Aug 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

03 Aug 2021 09:00:01 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

03 Aug 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

27 Jul 2021 08:00:01 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

20 Jul 2021 07:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma

16 Jun 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference

15 Jun 2021 16:05:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

07 Jun 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

01 Jun 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit

14 May 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development

10 May 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

06 May 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio

06 May 2021 06:04:47 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

01 Apr 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer

22 Mar 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

25 Feb 2021 06:45:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update

25 Feb 2021 06:30:00 By Nasdaq GlobeNewswire
SpringWorks Therapeutics to Present at Upcoming Investor Conferences

22 Feb 2021 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
5
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.